Morgan Stanley Belite Bio, Inc Call Options Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLTE
# of Institutions
24Shares Held
278KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY168KShares$9.5 Million0.15% of portfolio
-
State Street Corp Boston, MA20KShares$1.13 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC18.3KShares$1.04 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY14.6KShares$827,9580.0% of portfolio
-
Ubs Group Ag12.2KShares$690,5490.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.41B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...